Manchester and London, UK, 26 August, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, announced today that it has signed a research collaboration agreement with Takeda Cambridge Limited ("TCB"), a UK subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. Under the agreement, C4XD's proprietary NMR-based technology will be applied across a number of TCB's therapeutic projects to enhance lead discovery and hit identification.
C4XD has the only technology in the world that can generate accurate, experimentally-derived 3D structures of drug molecules in just a matter of days. It can be used in conjunction with existing technologies for structure-based design such as X-ray co-crystallography. Equally, it can also be used when crystallography is unavailable, as is the case for certain GPCRs and ion channels.
Piers Morgan, CEO of C4X, said "We are delighted to partner with TCB, a leading pharma company with world class target identification and validation capabilities. This collaboration will provide increased visibility of the potential advantages and benefits of C4XD's technology."
Dr Andy Ayscough, Senior Director of Chemistry at TCB, commented: "We are pleased to partner with C4XD and are excited about the potential of this collaboration. C4XD has a highly innovative platform technology which complements our strong research base to accelerate product development."